根据公司2024年第四季度财报,维京医疗公司(Viking Therapeutics)当季每股亏损0.32美元,远高于分析师平均预期的每股亏损0.28美元。与去年同期相比,公司亏损扩大了28%,引发投资者担忧。
加之公司临床研究费用和相关开支继续上升,研发投入不断加大,导致当季净亏损高达3540万美元。尽管公司CEO表示取得了多项重大临床进展,但业绩未及预期,引发市场质疑公司前景。
消息公布后,维京医疗公司在夜盘大幅下挫,收盘时跌幅超过10%,引发市场广泛关注。一度因超乎预期的亏损和高昂研发开支而遭资金抛售。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.